A
Anna Spreafico
Researcher at University of Toronto
Publications - 18
Citations - 471
Anna Spreafico is an academic researcher from University of Toronto. The author has contributed to research in topics: Cancer & Cell cycle. The author has an hindex of 8, co-authored 18 publications receiving 230 citations. Previous affiliations of Anna Spreafico include Princess Margaret Cancer Centre & Anschutz Medical Campus.
Papers
More filters
Journal ArticleDOI
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
Scott V. Bratman,Scott V. Bratman,S. Y. Cindy Yang,S. Y. Cindy Yang,Marco A. J. Iafolla,Marco A. J. Iafolla,Zhihui Liu,Zhihui Liu,Aaron R. Hansen,Aaron R. Hansen,Philippe L. Bedard,Philippe L. Bedard,Stephanie Lheureux,Stephanie Lheureux,Anna Spreafico,Anna Spreafico,Albiruni Ryan Abdul Razak,Albiruni Ryan Abdul Razak,Svetlana Shchegrova,Maggie C. Louie,Paul Billings,Bernhard Zimmermann,Himanshu Sethi,Alexey Aleshin,Dax Torti,Kayla Marsh,Jenna Eagles,Iulia Cirlan,Youstina Hanna,Derek L. Clouthier,Scott C. Lien,Scott C. Lien,Pamela S. Ohashi,Pamela S. Ohashi,Wei Xu,Wei Xu,Lillian L. Siu,Lillian L. Siu,Trevor J. Pugh,Trevor J. Pugh +39 more
TL;DR: The potential for broad clinical utility of ctDNA-based surveillance in patients treated with ICB is demonstrated, and 12 patients with ct DNA clearance during treatment were alive with median 25 months follow up.
Journal ArticleDOI
Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.
Anna Spreafico,Shao Hui Huang,Wei Xu,Roberta Granata,Chen Shin Liu,John Waldron,Eric X. Chen,Jolie Ringash,A. Bayley,Kelvin K. W. Chan,Andrew Hope,John Cho,Albiruni R. Razak,Aaron R. Hansen,Raymond Woo-Jun Jang,Bayardo Perez-Ordonez,Ilan Weinreb,Paolo Bossi,Ester Orlandi,Lisa Licitra,Yuyao Song,Brian O'Sullivan,Lillian L. Siu,John Kim +23 more
TL;DR: A survival benefit of cisplatin dose >200 mg/m2 is evident for HPV- LAHNC patients, but not for HPV+ cohort overall, although the T4 or N3 subset may benefit from a higher cumulative cisPlatin dose.
Journal ArticleDOI
Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma.
Justin M. Burgener,Justin M. Burgener,Jinfeng Zou,Zhen Zhao,Yangqiao Zheng,Shu Yi Shen,Shao Hui Huang,Shao Hui Huang,Sareh Keshavarzi,Wei Xu,Fei-Fei Liu,Fei-Fei Liu,Geoffrey Liu,Geoffrey Liu,John Waldron,John Waldron,Ilan Weinreb,Ilan Weinreb,Anna Spreafico,Anna Spreafico,Lillian L. Siu,Lillian L. Siu,John R. de Almeida,John R. de Almeida,David P. Goldstein,David P. Goldstein,Michael M. Hoffman,Daniel D. De Carvalho,Daniel D. De Carvalho,Scott V. Bratman,Scott V. Bratman +30 more
TL;DR: In this paper, the authors demonstrate tumor-naive detection of ctDNA by simultaneous profiling of mutations and methylation, using locoregionally confined head and neck squamous cell carcinoma (HNSCC) as an example.
Journal ArticleDOI
Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
Todd M. Pitts,Erica L. Bradshaw-Pierce,Erica L. Bradshaw-Pierce,Erica L. Bradshaw-Pierce,Stacey M. Bagby,Stephanie L. Hyatt,Heather M. Selby,Anna Spreafico,John J. Tentler,Kelly L. McPhillips,Peter J. Klauck,Anna Capasso,Jennifer R. Diamond,S. Lindsey Davis,Aik Choon Tan,John J. Arcaroli,Alicia Purkey,Wells A. Messersmith,Jeffery A Ecsedy,S. Gail Eckhardt +19 more
TL;DR: The data suggest that the addition of alisertib to standard therapies in colorectal cancer if pursued clinically, will require further investigation of patient selection strategies and these combinations may facilitate future clinical studies.
Journal ArticleDOI
Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models.
S. Lindsey Davis,Kelli M. Robertson,Todd M. Pitts,John J. Tentler,Erica L. Bradshaw-Pierce,Erica L. Bradshaw-Pierce,Erica L. Bradshaw-Pierce,Peter J. Klauck,Stacey M. Bagby,Stephanie L. Hyatt,Heather M. Selby,Anna Spreafico,Jeffrey Ecsedy,John J. Arcaroli,Wells A. Messersmith,Aik Choon Tan,S. Gail Eckhardt +16 more
TL;DR: In this paper, the combination of an Aurora A kinase and MEK inhibitor was evaluated in pre-clinical colorectal cancer models, with a focus on identifying a subpopulation in which it might be most effective.